FIP activities against counterfeit medicines
FIP Statement on counterfeit medicines
In 1999, FIP adopted a statement on counterfeit medicines during the Council meeting at the FIP Congress in Barcelona. Because of the growing and changing aspect of this major public health care issue, FIP has updated its Policy statement on counterfeit medicines in 2003 during its Council meeting at the FIP Congress in Sydney. You can download this statement on our website here. This statement is a strong political message of the pharmacists’ profession to support the fight against counterfeit medicines to protect the safety of their patients.
Collaboration with other international organisations
1. IMPACT
In 2006, the World Health Organization (WHO) established an international medical products anti-counterfeiting taskforce (IMPACT), which is a voluntary grouping of governments, organisations, institutions, agencies and associations from developing and developed countries aimed at sharing expertise, identifying problems, seeking solutions, coordinating activities and working towards the common goal of fighting counterfeit medical products. IMPACT aims at ensuring appropriate regional representation, including in particular from developing countries. Since the inception of IMPACT, FIP, representing the World Health Professions Alliance (WHPA) has been leading the IMPACT Working Group on Communications. A series of advocacy activities, including the development of materials, such as the WHPA toolkit on counterfeit medicines for health professionals and patients have been made.
For further information, please see http://www.who.int/impact/en/index.html
2. Council of Europe
In 2003 the Council of Europe established an Ad-hoc group on counterfeit medicines and since 2004, FIP has been providing support and working within this group to fight counterfeit medicines. In 2008, this Ad-hoc group became the Committee of Experts on Minimising public health risks posed by counterfeiting medical products and related crimes (CD-P-PH/CMED). FIP participation in this Committee was confirmed.
This Committee of Experts meets at least twice every year in Strasbourg.
For further information, please see http://www.edqm.eu/en/CD-P-CMED-Committee-of-Experts-on-minimising-the-public-health-risks-posed-by-counterfeiting-of-medical-products-and-related-crimes-CD-P-PHCMED-1330.html
3. World Health Professions Alliance
FIP is one of the founding members of the World Health Professions Alliance (WHPA) which gathers organisations representing medical doctors, pharmacists, nurses and dentists.
In 2008, the WHPA developed a communication toolkit aiming at raising awareness on counterfeit medicines among health professionals and providing some tools and strategies for detecting counterfeit medicines and for safely informing colleagues and patients.
This toolkit includes:
- An overview of the situation and suggestions as to what health professionals can do to help fight counterfeit medicines
- A reporting form that can be copied and used to report any suspected counterfeit (This form serves as a model and does not replace any existing ones in-country)
- A visual inspection check list that can be used if a counterfeit medicine is suspected
- An information leaflet that you can share with colleagues
- A patient information leaflet for distribution to patients or in community areas
- A poster that can be put in community pharmacy windows
Creating specific and practical tools for pharmacists
1. Tool for visual inspection
This document has been produced by the International Council of Nurses in partnership with the United States Pharmacopoeia (USP) and modified by the Military and Emergency Pharmacists Section of FIP. The tool is designed to help health professionals carry out a visual inspection of medicines for signs of counterfeiting such as improper packaging, labeling or description of dosage. All suspicious products with incorrect labels, missing information about the strength, dosage, or expiration date should be reported to the appropriate national authority or to the WHO or FIP.
Download English version here
Download Spanish version here
Download French version here
Download German version here
Download Dutch version here
2. Guide for pharmacists
FIP has developed a framework to facilitate the creation of a guide for pharmacists on counterfeit medicines. This document is available to FIP member organisations in English, French and Spanish and has been validated by the IMPACT working group on Communications.
This document suggests organizations and key elements to be included in a national guide for pharmacists. It also provides member organizations with some texts and indicates which part of the text should be updated in accordance to national situation.
Are you a member organisation of the FIP? Login on here to download the Guide. If you have any question on its application and on its content, please email us at profession@fip.org
Raising awareness and educating pharmacists and their leaders.
FIP has published several articles targeting pharmacists in their fight against counterfeit medicines.
You will find below a copy of some of these articles, reprinted with permission from Pharma Publishing and Media Europe:
- Xuanhao Chan, Ton Hoek, Valerio Reggi. Counterfeit medicines – it will never happen to me. Eur J Hosp Pharm Prac. 2008;14(2):55-57.
- Luc Besançon. The role of hospital pharmacists in counterfeit medicines. Eur J Hosp Pharm Prac. 2008;14(2):65-66.
- Xuanhao Chan and Luc Besançon. Safe internet buying of medicines: why and how pharmacists should help. Eur J Hosp Pharm Prac. 2008;14(3):61-63.
Copyright (C) 2008 Pharma Publishing & Media Europe. All rights reserved.
Moreover, during its previous congresses, FIP organised many conferences on counterfeit medicines to sensitise pharmacists and pharmacy leaders on the increasing risks and dangers for patients.
You will find below the presentations of the last Congresses sessions dedicated to Counterfeit medicines:
1) 2008 Congress in Basel: Combating counterfeit medicines in Africa
Chair: Valerio Reggi, World Health Organization, Switzerland
- Counterfeit medicines in Africa today – Utilising WHO/IMPACT tools and resources
Valerio Reggi, WHO, Switzerland
- Building effective national strategies to better address counterfeit medicines in African countries – Expanding GDP, GPP and Pharmacovigilance systems
Ilisa Bernstein, Food & Drug Administration, USA
- Strengthening African borders in combating counterfeit medicines – The need for enforcement: Part 1 and Part 2
Ziad Nassour, CIOPF, Lebanon
- Country specific case studies – Best practices to combat counterfeit medicines and to protect public health
Luc Besançon, International Pharmaceutical Federation (FIP), The Netherlands
- A law enforcement perspective on effective risk communications about counterfeit medicines: Part 1 and Part 2
Michael Tshinavha, Border Control Coordinating Committee, South Africa
2) 2007 Congress: BPP/BPS Joint symposium on Counterfeit medicines (part I)
Chairs: Jeffrey Gren, Office of Health Consumer Goods, USA and Nancy Blum, United States Pharmacopeia, USA
- IMPACT update
Valerio Reggi, World Health Organization, Switzerland
- Trade and commerce perpective
Jeffrey Gren, Office of Health Consumer Goods, USA
- Regional approaches to monitoring drug quality
Nancy Blum, United States Pharmacopeia, USA
- Track and Trace of shipments
Harvey Bale, International Federation of Pharmaceutical Manufacturers & Associations, Switzerland
- Analytical and surveillance
Shaohong Jin, National Institute for the Control of Pharmaceutical and Biological Products, China
3) 2007 Congress: BPP/BPS Joint Symposium on Counterfeit medicines (part II)
Chair: Jane Nicholson, FIP Working Group on Counterfeit medicines, UK
- Combating counterfeit medicines in the Guangdong, China
Zhang Jing Hua, Food and Drug Administration Guangdong, China
- Consumer advice and public awareness campaign
Jane Nicholson, FIP Working Group on Counterfeit medicines, UK
- A model to estimate the extent of counterfeit medicines
Prafull Sheth, South East Asia Regional Forum, India
- Modern Screening methods in action: presentation not available
Tony Moffat, University of London, UK
- Counterfeiting drugs is murder – Current national legislative responses [link]
Michael Anisfield, Globepharm Consulting, USA
4) 2006 Congress: Combating counterfeiting (part 1)
Co-Chairs: Tom Sam, FIP Industrial Pharmacy Section, the Netherlands and José Maldonado, Evidence Saluções Farmacêuticas Ltda, Brazil.
- Global perspective
Valerio Reggi, WHO, Switzerland
- The ANVISA effort on combating counterfeit medicines in Brazil - National Plan on Combating Counterfeit
Carlos Alberto Cavalcanti Gallindo Filho, Agência Nacional de Vigilância Sanitária, Brazil.
- FIP anti-counterfeiting activities
Jane Nicholson, FIP Working Group on Counterfeit medicines, UK
- Government action: presentation not available
Dora Akunyili, National Agency for Food and Drug Administration and Control, Nigeria
5) 2006 Congress: Combating counterfeiting (part 2)
Co-Chairs: Frans van der Vaart, FIP Laboratories and Medicines Control Services Section, the Netherlands.
- Screening tests
Thomas Layloff, Partnership for Supply Chain Management, USA
- A powerful screening system for the detection of counterfeits developed by China[Link]
Shaohong Jin, National Institute for the Control of Pharmaceutical and Biological Products, China
- Analyses for the future
Tony Moffat, University of London, UK
- Action by industry: presentation not available
Tom Kubic, Pharmaceutical Security Institute, USA

